Biocorp could achieve decisive milestones in 2017
For the past 2 years, Biocorp has initiated major business transformations in order to become a key player in the booming market of connected health. The company has developed a range of connected devices addressing major healthcare issues. The company made significant advances in 2016 by signing 4 partnerships agreements with pharmaceutical players. Based on these agreements, Biocorp and its partners initiated preliminary studies assessing the feasibility and the performance of Biocorp’s connected devices in various indications. Since several milestones are expected on these studies in 2017, this year could be decisive for the company. Our target price on Biocorp is € 17.00 / share
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.